Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 113 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Rovalpituzumab tesirine for the treatment of relapsed or refractory small cell lung cancer	Rovalpituzumab tesirine (SC16LD6.5; Rova-T)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2017	View \| Download
Sacituzumab govitecan for previously treated advanced non-small cell lung cancer	Sacituzumab Govitecan (IMMU-132; Trodelvy)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Savolitinib with osimertinib for treating EGFR- mutated, MET-overexpressed advanced non-small-cell lung cancer	Osmertinib , Savolitinib (AZD6094)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2024	View \| Download
Selpercatinib for metastatic RET fusion-positive non-small cell lung cancer	Selpercatinib (LOXO-292; LY3527723)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2019	View \| Download
Selpercatinib for previously untreated advanced RET fusion-positive non-small cell lung cancer	Selpercatinib (LOXO-292; LY3527723)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Selpercatinib for treating advanced solid tumours with RET gene fusion in people aged 12 years and older	Selpercatinib (LOXO-292; LY3527723)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Serplulimab with chemotherapy for treating previously untreated extensive stage small-cell lung cancer	Serplulimab (HLX10)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2023	View \| Download
Sintilimab in combination with pemetrexed and platinum chemotherapy for advanced or metastatic non-small cell lung cancer	Carboplatin (Paraplatin) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) , Sintilimab (IBI 308; IBI 380; Tyvyt)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Subcutaneous atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer	Atezolizumab (Tecentriq; MPDL3280A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Tarlatamab for relapsed/refractory small-cell lung cancer	Tarlatamab	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2023	View \| Download